Edwards Lifesciences (EW) Change in Accured Expenses (2009 - 2026)

Edwards Lifesciences has reported Change in Accured Expenses for 18 years, with the latest figure at $123.7 million in Q2 2026.

• On a quarterly basis, Change in Accured Expenses rose 19.29% year-over-year to $123.7 million in Q2 2026; TTM through Jun 2026 was $171.4 million, a 532.47% increase from a year earlier, with the FY2025 full-year figure at $395.1 million, up 341.45% from the prior year.
• Change in Accured Expenses was $123.7 million for Q2 2026 at Edwards Lifesciences, up from -$347.1 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $226.1 million in Q3 2025, with the low at -$347.1 million in Q1 2026.
• Average Change in Accured Expenses over 5 years is $21.4 million, with a median of $31.6 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses sank 1074.19% in 2022, then soared 5541.94% in 2025.
• Over 5 years, Change in Accured Expenses stood at $34.3 million in 2022, then decreased by 2.62% to $33.4 million in 2023, then sank by 109.28% to -$3.1 million in 2024, then jumped by 5541.94% to $168.7 million in 2025, then retreated by 26.67% to $123.7 million in 2026.
• The last three Change in Accured Expenses figures came in at $123.7 million (Q2 2026), -$347.1 million (Q1 2026), and $168.7 million (Q4 2025), per Business Quant data.